Lifeboat Foundation

Synchron has developed a Brain-Computer Interface that uses pre-existing technologies such as the stent and catheter to allow insertion into the brain without the need for open brain surgery.

Read the CNET article for more info:
You Might Not Need Open Brain Surgery to Get Mind Control https://cnet.co/3sZ7k67

Continue reading “Brain-Computer Interface: No Open Brain Surgery Required 🧠” »

Bacancy is proud to announce the launch of a new AI tool, MedPreGPT, to help doctors with medicine prescriptions. This system enables doctors who all are using it for internal purposes to give accurate prescription recommendations privately without wasting any time. Compared to AI models like ChatGPT, this tool is specially trained with vast medical data and makes relevant suggestions. This innovative tool is made to enhance patient care, reduce human errors, and streamline the prescription process.

Doctors are only humans and they indeed work under intense work pressure and workload. Mistakes can happen in such an environment. Today’s healthcare providers use ChatGPT and Google’s Gemini for medicine recommendations, which is not completely wrong, but those tools might give false information. Bacancy has recognized the problem and found MedPreGPT to give accurate medical prescriptions.

The following are features of MedPreGPT Provides AI-based prescription recommendations according to symptoms and history. It is integrated with electronic health records (EHRs) for workflow ease. It provides multilingual support for healthcare professionals across the world Provides healthcare providers with updates in real time, regarding the latest clinical guidelines and drug interactions to ensure true care.

Researchers at Karolinska Institutet have succeeded in delivering targeted cancer treatment via small membrane bubbles that our cells use to communicate. A new study published in Nature Biomedical Engineering shows that the treatment reduces tumour growth and improves survival in mice.

In a recent study published in Nature Cancer, a team of researchers investigated the unique structure of deoxyribonucleic acid (DNA) in extracellular vesicles (EVs) and its role in cancer progression.

The study examined how EV-DNA, through its association with histones, influences immune cell responses and impacts the pre-metastatic niche. It also explored how it could serve as a predictive biomarker for metastasis, especially in colorectal cancer.

The study highlights how EV-DNA packaging influences immune responses and its promise as a biomarker for assessing colorectal cancer metastasis risk.

Continue reading “Extracellular vesicle DNA regulates immune responses and suppresses liver metastasis” »

Increasing the levels of chemicals naturally produced in the body called endocannabinoids may thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs’ ability to relieve pain, according to Weill Cornell Medicine investigators working with researchers from The Center for Youth Mental Health at NewYork-Presbyterian. Endocannabinoids bind to cannabinoid receptors throughout the body that regulate activities, such as learning and memory, emotions, sleep, immune response and appetite.

Opioids prescribed to control pain can become addictive because they not only dull pain, but also produce a sense of euphoria. The preclinical study, published Nov. 29 in Science Advances, may lead to a new type of therapeutic that could be taken with an opioid regimen to only reduce the rewarding aspect of opioids.

In 2023, opioid abuse or overuse was responsible for more than 80,000 deaths, fueling a national crisis, according to the U.S. Centers for Disease Control and Prevention. Illegal recreational drugs were ultimately responsible for many deaths, but not all of them. “When someone has surgery and is taking opioids for pain management, there’s always a risk of developing a dependence on these drugs,” said senior author Dr. Francis Lee, chair of the Department of Psychiatry at Weill Cornell Medicine and psychiatrist-in-chief at New York-Presbyterian/Weill Cornell Medical Center.

Drug-induced toxicity is one of the leading reasons new drugs fail clinical trials. Machine learning models that predict drug toxicity from molecular structure could help researchers prioritize less toxic drug candidates. However, current toxicity datasets are typically small and limited to a single organ system (e.g., cardio, renal, or liver). Creating these datasets often involved time-intensive expert curation by parsing drug label documents that can exceed 100 pages per drug. Here, we introduce UniTox[1][1], a unified dataset of 2,418 FDA-approved drugs with drug-induced toxicity summaries and ratings created by using GPT-4o to process FDA drug labels. UniTox spans eight types of toxicity: cardiotoxicity, liver toxicity, renal toxicity, pulmonary toxicity, hematological toxicity, dermatological toxicity, ototoxicity, and infertility. This is, to the best of our knowledge, the largest such systematic human in vivo database by number of drugs and toxicities, and the first covering nearly all FDA-approved medications for several of these toxicities. We recruited clinicians to validate a random sample of our GPT-4o annotated toxicities, and UniTox’s toxicity ratings concord with clinician labelers 87–96% of the time. Finally, we benchmark a graph neural network trained on UniTox to demonstrate the utility of this dataset for building molecular toxicity prediction models.

### Competing Interest Statement.

The authors have declared no competing interest.

It solves in five minutes a problem computers now would need-1 years to work out, Google says.

A concerning new study from the Apollo AI Safety Research Institute has revealed that leading AI models, particularly the O1 model, demonstrate sophisticated deceptive behaviors when faced with conflicts between their programmed goals and developer intentions.

The research tested multiple frontier AI models, including O1, Claude 3.5 Sonnet, Claude 3 Opus, Gemini 1.5 Pro, and LLaMA 3.1, for their capacity to engage in what researchers term “in-context scheming” – the ability to recognize and execute deceptive strategies to achieve their goals.

Biobanks are an obvious use case for DNA data storage. “With this technology, you could convert a biobank that is the size of a football field into something that can fit with everything in the palm of your hand,” says Banal. With encapsulation technologies, the DNA samples can be stored at room temperature. Compared to storing samples in freezing conditions in conventional biobanks or data centers that require extensive cooling, this has significantly lower energy consumption.

Until recently, scientific and medical applications were the sole drivers behind storing data in DNA. New research could broaden its scope to cryptography and nanotechnology. Another interesting development is the emerging intersection of DNA data storage and DNA computing. Indexing methods for DNA data retrieval mentioned earlier are an early example of that. Today, one of the most pressing commercial drivers of the technology is the data centers.

As researchers and startups chip away at its limitations, DNA data storage is becoming a viable commercial solution for storing all kinds of data at scale. The DNA Data Storage Alliance, a consortium founded in 2020, counts legacy data storage giants such as Western Digital and Seagate among its members.